Chondroprotectant Injections Versus Oral Joint Supplements for Dogs

By Lauren Cochran, DVM, DACVIM

✓ Medically reviewed by Lauren Cochran, DVM, DACVIM — August 13, 2026 For general education — not a substitute for veterinary care.

Comparisons · August 16, 2026 · 5 min read

One is an FDA-approved injectable with a defined dosing schedule; the other is a supplement aisle full of mixed evidence — here's how I sort them.

Otis was a nine-year-old Labrador, sixty-eight pounds, the kind of dog who used to launch himself off the porch steps without a thought. His owner noticed the change over a single winter: he started pausing at the bottom of the stairs, taking them one at a time instead of two, and he stopped jumping onto the tailgate of the truck he’d ridden in his whole life. By the time they got to me, she’d already tried a glucosamine chew from the pet store for about six weeks with what she described as “maybe a little” improvement — she wasn’t sure, and honestly, neither was I, because that’s the trouble with a lot of what happens in the joint-supplement aisle. So we talked about the other option sitting on the table: a chondroprotectant injection series, with a real dosing schedule and an FDA approval behind it, instead of another bag of chews.

This is the question I get from owners almost every time a dog’s gait starts to change: do we go straight to the injectable, or try the oral route first? The honest answer depends on what each option is actually doing in the joint, and what the evidence says it does — not on which one is easier to hand over the counter.

What the injectable is actually doing

Adequan Canine, whose active ingredient is polysulfated glycosaminoglycan (PSGAG), is the only DailyMed-listed, FDA-approved injectable indicated for non-infectious degenerative or traumatic arthritis of the synovial joints in dogs. The labeled dose is 4.4 mg/kg by intramuscular injection, twice weekly, for up to eight injections over four weeks. That’s a defined loading protocol, not an indefinite daily habit — a meaningful difference from the oral category. PSGAG is a semisynthetic compound structurally related to the glycosaminoglycans that already make up cartilage matrix, and it’s believed to work by inhibiting the enzymes that break cartilage down while supporting the synovial fluid that lubricates the joint. In the pivotal efficacy trial referenced on the DailyMed label, adverse reactions were mild and self-limited — transient injection-site soreness, occasional loose stool — reported after roughly 2% of injections.

What I want owners to understand is that this is a drug with a regulatory approval behind a specific claim, administered on a schedule a veterinarian controls. That’s a different category of evidence than “supports joint health,” and it should be treated differently in a treatment plan.

Where oral joint supplements actually stand

The oral aisle is not one thing — it’s glucosamine, chondroitin sulfate, omega-3 fatty acids, and green-lipped mussel extract, usually blended together, and the evidence behind each ingredient varies more than the marketing suggests. A randomized, double-blind, positive-controlled trial published on PubMed found that dogs given an oral glucosamine hydrochloride and chondroitin sulfate combination showed statistically significant improvement in pain and weight-bearing scores by day 70 — but the response was slower to appear than in the carprofen comparison group, and more recent placebo-controlled work has failed to replicate force-plate improvements at 4 and 6 weeks. A 2024 review in the Journal of Small Animal Practice summarized this honestly: the evidence for glucosamine and chondroitin in canine osteoarthritis is genuinely mixed, and some of the reported owner-perceived improvement looks like caregiver placebo effect rather than an objective change.

Omega-3 fatty acids are the strongest performer in this category. A randomized, double-blinded clinical trial published in the Journal of the American Veterinary Medical Association found that dietary supplementation with fish oil omega-3 fatty acids improved weight-bearing in dogs with osteoarthritis compared to controls. That’s a real, replicated signal, and it’s one reason I’ll usually put a dog on a fish-oil product with a stated EPA/DHA dose before I reach for a glucosamine blend with a vague label.

If you’re comparing supplement formats — whether the fish oil comes as a chew, a powder, or a liquid — the practical difference in absorption and dosing precision is worth understanding on its own; I go through that in Chew vs Powder vs Liquid Supplements for Dogs. And if what you’re actually weighing is glucosamine against MSM specifically, I’ve broken that comparison down separately in Glucosamine Versus MSM for Dog Joint Pain.

In my practice, I see this play out with older dogs almost every month. A twelve-year-old spayed female mixed breed, around forty pounds, came in because her owner noticed she’d stopped greeting them at the door with her usual tail-wagging bounce, and she was slower getting up from the kitchen floor after naps — a change the owner clocked over about eight weeks. We started with a joint-focused diet change and an omega-3 supplement dosed to her weight, alongside a short course of the injectable series, because her radiographs showed moderate hip changes that I didn’t think oral support alone would touch quickly enough. Within the loading month, her owner reported she was initiating stairs again without hesitation. That’s one dog, not a trial — but it’s the kind of case that shapes how I sequence these two tools rather than picking one exclusively.

Read the data closely before crowning anything

Here’s where I land, and I want to be direct about it because owners deserve a recommendation, not a shrug: for a dog with radiographically confirmed osteoarthritis and a meaningful functional change — trouble with stairs, reluctance to jump, a visibly altered gait — I favor starting the PSGAG injection series, because it’s the only option in this comparison with an FDA-approved indication and a defined dosing protocol behind it. Oral omega-3 supplementation earns a place alongside it, not instead of it, because the JAVMA evidence for fish oil is real. Glucosamine and chondroitin blends I treat as optional adjuncts at best; I don’t build a treatment plan around them given how inconsistent the trial data has been.

The strongest counterargument, and I take it seriously, is cost and convenience: an injection series requires clinic visits, and oral supplements don’t. For an owner who genuinely cannot manage the visit schedule, a well-dosed omega-3 product is a defensible starting point rather than nothing. But I don’t think convenience should be mistaken for equivalent evidence, and I’d rather an owner know that going in than assume a chew is doing what an injectable series does.

If your dog is showing the pattern Otis showed — hesitation on stairs, a missed jump, a slower rise from the floor — the practical next step is a veterinary exam and imaging before you commit to either path, because the right combination depends on what’s actually happening in that joint. It’s also worth ruling out whether you’re looking at arthritis at all versus ordinary aging stiffness, a distinction I walk through in Arthritis vs. Normal Aging Stiffness in Dogs.